这是一项先导研究，旨在识别伴有淋巴结或远端转移的胃癌患者中的新型治疗分子靶点。所有在威尔斯亲王医院确诊为伴有转移的胃癌患者均将接受资格筛查。
适应症：Stomach Neoplasms, Benign
入组条件
纳入标准
- Patients age \>= 18, \<= 80 years old
- Performance status (WHO) \<=2
- Gastric adenocarcinoma with lymph node metastasis or distant metastasis such as liver metastases, lung metastases, bone metastases, peritoneum metastases
- Patients with isolated ovarian metastasis could be included
- Patients who will be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy
- Ability to give written consent before the commencement of treatment
排除标准
- Patient who will not be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy
- Pregnancy or breastfeeding
- Patients with irreversible coagulation disorders
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。